Additional file 1 of Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Additional file 1: Supplementary Figure 1. Immunohistochemistry (IHC) of the PD-L1 control. (a) Positive control of PD-L1 staining (Dako 22C3, tonsil). (b) Positive control of PD-L1 staining (Dako 28–8, tonsil)
Lin, Y. (Contributor), Wen, K. (Creator), Sung, P. (Contributor), Chou, Y. (Creator), Liew, P. (Contributor), Chen, L. (Contributor), Huang, R. (Creator), Lai, H. (Contributor), Chang, L. (Contributor) (2020). Additional file 1 of Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. Figshare. 10.6084/m9.figshare.13352142.v1